December 10, 2007

ENTREMED PRESENTS RESULTS FOR ITS LEAD AURORA KINASE–ANGIOGENESIS INHIBITOR

EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of preclinical results for its lead Aurora kinase-angiogenesis inhibitor, ENMD-981693 The data were presented by EntreMed scientists at the American Society of Hematology Annual Meeting being held December 8-11, 2007 in Atlanta, Georgia.
PDF Download

read more »

December 06, 2007

MerLion Pharmaceuticals Wins Prestigious Pharmaceutical Industry Scrip Award

MerLion Pharmaceuticals (MerLion) today announced that it was awarded ‘Best Company in an Emerging Market’ at the industry’s annual Scrip Awards held in London on December 4th.
PDF Download

read more »

December 04, 2007

ENTREMED COMMENCES PHASE 2 STUDY WITH MKC-1 IN PANCREATIC CANCER

EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has commenced a multi-center Phase 2 clinical trial with MKC-1 in patients with advanced pancreatic cancer. The primary objectives of this study will be to determine the antitumor activity of orally-administered MKC-1 in unresectable or metastatic pancreatic cancer patients who have failed at least one prior  chemotherapy regimen. The study will also assess the safety, tolerability and overall median survival time of pancreatic cancer patients treated with MKC-1. Massachusetts General Hospital Cancer Center is the lead institution for the study and Eunice Kwak, M.D., Ph.D., Assistant in Medicine, Tucker Gosnell Center for Gastrointestinal Cancers, will serve as the principal investigator.
PDF Download

read more »

November 27, 2007

IKARIA’S INOMAX® (NITRIC OXIDE) FOR INHALATION APPROVED IN AUSTRALIA

Ikaria Holdings, Inc., through its subsidiary INO Therapeutics LLC, announced today that it has received approval from Australia’s regulatory body, the Therapeutic Goods Administration (TGA), for INOmax (nitric oxide) for inhalation. INOmax has been designated an orphan drug by the TGA. The Australian Orphan Drug Act provides a pathway for the development of medical products to treat rare disorders. INOmax is the first pharmaceutical gas approved in Australia, a designation it also has received in the United States, Europe, Canada, Singapore and several countries in Latin America. INOmax is indicated for the treatment of near- and full-term newborns who suffer from hypoxic respiratory failure (HRF), a potentially life-threatening condition that keeps babies’ lungs from delivering enough oxygen to their bodies.
PDF Download

read more »

October 25, 2007

ENTREMED SHOWS INCREASED SURVIVAL WITH MKC-1 IN PRECLINICAL RENAL CELL CANCER MODEL

EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of results for its cell cycle inhibitor, MKC-1, in preclinical renal cell carcinoma (RCC) models. The results were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, California.
PDF Download

read more »

October 25, 2007

ENTREMED REPORTS PHASE 1 PK AND PRECLINICAL EFFICACY RESULTS FOR ENMD-1198

EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of interim Phase 1 pharmacokinetic results for its antimitotic agent, ENMD-1198, together with preclinical antitumor activity results. The data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held this week in San Francisco, California.
PDF Download

read more »

October 24, 2007

ENTREMED PRESENTS RESULTS FOR PANZEM® NCD PHASE 2 OVARIAN CANCER STUDY

EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of results for its Phase 2, open-label study for Panzem® NCD (2ME2 or 2-methoxyestradiol) in patients with ovarian cancer. The results were presented by Dr. Daniela Matei, principal investigator for the study representing the Hoosier Oncology Group, at the AACR-NCIEORTC International Conference on Molecular Targets and Cancer Therapeutics being held this week in San Francisco, California.
PDF Download

read more »

October 16, 2007

ENTREMED APPOINTS SENIOR VICE PRESIDENT OF RESEARCH AND DEVELOPMENT

EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that Kenneth W. Bair, Ph.D. has been appointed its Senior Vice President, Research and Development. Dr. Bair has also been elected an executive officer of EntreMed by the Board of Directors, reporting to James S. Burns, President & CEO.
PDF Download

read more »

September 26, 2007

MerLion Pharmaceuticals initiates Phase 1 clinical study of Finafloxacin, a novel ‘pH activated’ antibiotic

MerLion Pharmaceuticals (MerLion) announces today that it has commenced Phase 1 clinical trials of the novel antibiotic, finafloxacin. This compound demonstrates a unique acid activated activity, which differentiates it from existing antibiotic therapies and opens up exciting new product opportunities.
PDF Download

read more »

July 31, 2007

Entremed Article in Drug Discovery and Development - A Wild Ride

New Focus and FInancing sets Entremed back on track
PDF Download

read more »

July 02, 2007

MerLion Pharmaceuticals initiates Phase I clinical study of Friulimicin B, a novel lipopeptide antibiotic

MerLion Pharmaceuticals (MerLion) announces today the commencement of Phase I clinical trials of the novel lipopeptide antibiotic, friulimicin B (friulimicin). The drug candidate is active against a broad spectrum of gram positive multi drug resistant, invasive pathogens and is the only experimental antibiotic of its type in clinical trials.
PDF Download

read more »

June 19, 2007

Merck Serono and Ambrx to Collaborate on Development of Next Generation Growth Hormone Products

Ambrx growth hormone products designed to allow less frequent administration than current growth hormone daily dosing regimens
PDF Download

read more »

June 06, 2007

Fierce Biotech Names MerLion Pharmaceuticals as One of the “Fierce 15" Biotech Companies of 2007

MerLion Pharmaceuticals announced today that it has been included in the annual FierceBiotech “Fierce 15” list, designating it as one of the top biotech companies of 2007. The editors of FierceBiotech evaluated hundreds of privately-held firms based on company vision, revenue potential, quality of deals, strength of technology, partnerships, and competitive market position. MerLion Pharmaceuticals was determined to be one of the “fiercest,” proven by their creativity, rapid corporate development, and innovations in the industry.
PDF Download

read more »

June 04, 2007

ENTREMED PRESENTS PHASE 2 RESULTS FOR PANZEM® CAPSULES IN MULTIPLE MYELOMA

EntreMed, Inc. (NASDAQ:ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of Phase 2 results for the capsule formulation of one of its lead oncology drug candidates, Panzem® (2-methoxyestradiol or 2ME2), in patients with relapsed and plateau phase multiple myeloma. The data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting being held this week in Chicago, Illinois. The study was conducted at the Mayo Clinic and the Dana-Farber Cancer Institute with Dr. Vincent Rajkumar and Dr. Paul Richardson as principal investigators, respectively.
PDF Download

read more »

May 29, 2007

ENTREMED COMMENCES PHASE 2 CLINICAL TRIAL COMBINING PANZEM® NCD AND TEMODAR IN BRAIN CANCER PATIENTS

EntreMed, Inc. (NASDAQ:ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the commencement of a Phase 2 combination study with Panzem® NCD (2-methoxyestradiol or 2ME2) and Temodar® (temozolomide) in patients with recurrent glioblastoma multiforme (GBM). Annick Desjardins, M.D., FRCPC, Associate in Medicine at the Preston Robert Tisch Brain Tumor Center at Duke University Medical Center will serve as principal investigator. The purpose of the single center, open-label study will be to determine progression free survival (PFS),
pharmacokinetics and safety in GBM patients receiving orally-administered Panzem® NCD in combination with Temodar®.
PDF Download

read more »

April 19, 2007

ENTREMED PRESENTS PRECLINICAL DATA FOR MKC-1 IN HEMATOLOGICAL CANCERS

EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of preclinical results for MKC-1, its novel cell cycle inhibitor. The data were presented by EntreMed scientists at the American Association for Cancer Research (AACR) Annual Meeting being held this week in Los Angeles, California.
PDF Download

read more »

February 28, 2007

IKARIA AND INVESTOR GROUP CLOSE TRANSACTION TO ACQUIRE INO THERAPEUTICS FROM LINDE IN $670 MILLION CASH AND STOCK MERGER, CREATING A WORLD LEADER IN CRITICAL CARE THERAPEUTICS

Ikaria Holdings, a newly formed investment company, closed today on its previously announced transaction to combine Ikaria, Inc., a biotechnology company, and INO Therapeutics, the world leader in gaseous drugs, including inhaled nitric oxide for the treatment of hypoxic respiratory failure in newborns. The transaction, valued at approximately $670 million, was financed by a group of private equity and venture capital investors led by New Mountain Capital, ARCH Venture Partners and Venrock Associates. INO Therapeutics was acquired from The Linde Group (Deutsche Börse: LIN), which retains an equity position in the new entity. The combined company, which is called Ikaria Holdings, has a leadership position in therapeutic gases and critical care medicine, a high-growth, multi-billion-dollar market. Its corporate headquarters is in Clinton, N.J., with operations in several other locations, including a research and development facility in Seattle.
PDF Download

read more »

February 22, 2007

IKARIA AND INVESTOR GROUP TO ACQUIRE INO THERAPEUTICS IN $670 MILLION CASH AND STOCK MERGER, CREATING A WORLD LEADER IN CRITICAL CARE THERAPEUTICS

Ikaria Holdings, a newly formed investment company, announced today the signing of a definitive agreement to combine Ikaria Inc., a biotechnology company, and INO Therapeutics, the world leader in gaseous drugs including inhaled nitric oxide for treatment of hypoxic respiratory failure in newborns. The transaction, valued at approximately $670 million, is being financed by a group of private equity and venture capital investors led by New Mountain Capital, ARCH Venture Partners and Venrock Associates. INO Therapeutics is being acquired from The Linde Group (Deutsche Börse: LIN), which will retain an equity position in the new entity. The combined company, which will be called Ikaria Holdings, will have a leadership position in therapeutic gases and critical care medicine, a high-growth, multi-billion-dollar market. Its corporate headquarters will be in Clinton, N.J., with operations in several other locations including a research and development facility in Seattle.
PDF Download

read more »

February 12, 2007

Evolution im Schnelldurchlauf

Neil Goldsmith hat schon in elf Biotechnologie-Start-ups gearbeitet. Seit zwei Jahren baut er nun in Allschwil die Evolva auf. Er hat aus dem Projekt bereits eine global
erfolgreiche Firma gemacht.
PDF Download

read more »

February 12, 2007

Ambrx Initiates Phase I/II Clinical Trial of Novel Human Growth Hormone Product Candidate

Ambrx Inc. announced today that it has initiated a Phase I/II clinical trial of ARX201, a novel, next-generation human growth hormone product candidate.
PDF Download

read more »

February 11, 2007

Omeros Raises More Than $63 Million in Financing

Omeros today announced that it has raised in excess of $63 million in an oversubscribed Series E equity financing. New investors, including Aravis Ventures, ARCH Venture Partners, subsidiaries of American Financial Group, Grosvenor Funds, Novartis Venture Fund, Southern Cross Capital, Stanley Medical Research Institute, Trevi Health Ventures and WRF Capital, participated alongside existing shareholders. The round was completed on terms that were consistent with those of Omeros’ previous financings and at a price that recognized the company’s increasing value.
PDF Download

read more »